Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. expects a significant increase in its 2025 annual net profit, projecting over RMB 240 million, a year-on-year growth of approximately 139.4%, and an operating revenue exceeding RMB 1.05 billion, with a year-on-year increase of about 34.6% [1][2] Financial Performance - The company anticipates a strong performance in 2025, driven by robust sales growth of core products, accelerated overseas business development, and continuous optimization of operational efficiency [1] - Key products such as Tongqiao Qilin™ blood flow guiding device, neurovascular guide wire, UltraFree® drug-eluting PTA balloon dilatation catheter, and ZYLOX Swan® venous intraluminal radiofrequency closure catheter have all seen rapid sales growth [1] - International sales revenue has more than doubled year-on-year, with increasing market penetration in key countries like Germany, France, and Italy [1] Strategic Initiatives - The company focuses on "innovation" and "internationalization" as core strategies to drive business layout and upgrades [2] - Several key innovative products have been approved for market launch, including ZYLOX Mammoth large lumen™ peripheral thrombectomy catheter and Tongqiao Feilong™ intracranial aneurysm embolization assist stent, achieving positive market performance [2] - The international strategy has made significant breakthroughs, with sales channels covering 83 countries and regions globally and over 80 strategic partnerships established with overseas partners [2] Future Outlook - The company plans to continue its commitment to innovation in the medical technology field, increasing R&D investment and accelerating international strategic layout [2] - A strategic acquisition of German company Optimed has been announced to further expand its presence in the European and global markets, enhancing the promotion and implementation of innovative products [2] - The company aims to provide high-quality and affordable innovative products and solutions for global patients while enhancing long-term value and sustainable returns for shareholders [2]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. (2190.HK) anticipates a significant increase in its 2025 annual net profit, projecting over RMB 240 million, a year-on-year growth of approximately 139.4%, alongside an expected revenue exceeding RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1][2] Group 1: Financial Performance - The company expects a net profit exceeding RMB 240 million for 2025, marking a substantial increase of approximately 139.4% compared to the previous year [1] - Projected revenue for 2025 is over RMB 1.05 billion, representing a year-on-year growth of around 34.6% [1] - The strong performance is attributed to robust sales growth of core products, accelerated overseas business development, and ongoing operational efficiency improvements [1] Group 2: Product and Market Development - Key products such as Tongqiao Qilin™ blood flow guiding device and UltraFree® drug-eluting PTA balloon dilation catheter have shown rapid sales growth [1] - The international business saw sales revenue increase by over 100% year-on-year, with improved market penetration in Germany, France, and Italy [1] - Several innovative products received approval for commercialization, including ZYLOX Mammoth large lumen™ peripheral thrombectomy catheter and Tongqiao Feilong™ intracranial aneurysm embolization assist stent [2] Group 3: Strategic Initiatives - The company is focusing on "innovation" and "internationalization" as core strategies to drive business layout and upgrades [2] - By the end of 2025, the company’s sales channels will cover 83 countries and regions globally, establishing strategic partnerships with over 80 overseas partners [2] - A strategic acquisition of German company Optimed was announced to enhance the company's presence in Europe and globally, facilitating the promotion of innovative products in international markets [2]